Cutaneous Lupus Erythematosus Epidemiology

Key Highlights

• Cutaneous Lupus Erythematosus (CLE) is a group of heterogeneous autoimmune disorders primarily affecting the skin and mucosal tissue, showing varying levels of association with systemic lupus erythematosus (SLE).
• Like SLE, the pathogenesis and clinical manifestations of Cutaneous Lupus Erythematosus are complex and heterogeneous, and genetic and environmental factors are involved in the development of Cutaneous Lupus Erythematosus.
• About 10% of all lupus cases are cutaneous, and 65% of people with systemic lupus will develop skin lupus.
• Skin involvement occurs in 70–80% of all patients with SLE during their disease, and skin lesions are the first disease manifestation to present in 20–25% of patients with SLE.
• Population-based studies on the epidemiology of Cutaneous Lupus Erythematosus are rare, and most available epidemiological data is based on hospital-based studies not necessarily meant to determine the true epidemiological trend.
• In 2022, the total diagnosed prevalent cases of Cutaneous Lupus Erythematosus were ~1,467,900 in the 7MM and China, which might reach ~1,984,400 cases by 2034 at a CAGR of 3%.
• Cutaneous Lupus Erythematosus affects all age groups but is rare in children and is more common in females with different proportions according to subtype.

DelveInsight’s “Cutaneous Lupus Erythematosus – Epidemiology Forecast – 2034” report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, Japan, and China.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan
• China

Study Period: 2021-2034

Cutaneous Lupus Erythematosus Understanding and Diagnostic Algorithm

Cutaneous Lupus Erythematosus Overview

Cutaneous Lupus Erythematosus (CLE) is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus, where the symptoms are restricted to the skin. Lupus Erythematosus (LE) is a chronic, autoimmune disease that affects multiple body organs and systems with a broad spectrum of symptoms. About the skin, there are lupus-specific skin lesions and non-specific skin lesions. Cutaneous Lupus Erythematosus is on one end of the spectrum, and severe systemic LE is on the other. Both of them can occur together and separately.

There are three broad types of cutaneous lupus: Acute, Subacute, and Chronic Cutaneous Lupus Erythematosus. The prototypical example of acute cutaneous lupus is the malar rash. Subacute cutaneous lupus (SCLE) usually involves rashes in sun-exposed areas, and this generally does not lead to scarring. Chronic cutaneous lupus can be subdivided into several cutaneous findings, including discoid, tumidus, profundus, and chilblains. The hallmark condition of chronic cutaneous lupus is discoid lupus erythematosus (DLE).

Cutaneous Lupus Erythematosus Diagnosis

To properly diagnose cutaneous manifestations of Lupus Erythematosus, the physician must first correctly classify the subtype and exclude systemic involvement of the disease. Cutaneous Lupus Erythematosus diagnosis should be based on the findings of patient history, clinical exam, laboratory studies, serology, histology, and direct immunofluorescence (DIF) exam of skin biopsies. Serology is routinely obtained at baseline to assess systemic involvement as well as guidance among the subsets of Cutaneous Lupus Erythematosus.

The histopathological picture for diagnosing Cutaneous Lupus Erythematosus is the golden standard combined with clinical and serological pictures. A biopsy cannot confidently discriminate between the three main subsets of Cutaneous Lupus Erythematosus since these will all show interface dermatitis.

A serological test of ANA and extractable nuclear antigens (ENAs) should be performed at baseline to assess possible systemic involvement. A routine blood and biochemistry test should be performed, including urinalysis for proteinuria. A visual check should also be performed before starting medication if antimalarial are considered.

Diagnosing Acute Cutaneous Lupus Erythematosus requires proper sub-type classification through a combination of physical examination, laboratory studies, histology, and antibody serology. Also, direct immunofluorescence and photo-provocation may confirm the diagnosis in some specific cases to exclude systemic disease.

In the case of sub-acute cutaneous lupus erythematosus, diagnosis is mainly based on clinical features and confirmed by histopathology. Severe systemic disease is less common in these patients. Also, for all the different cutaneous lupus erythematosus sub-types, a very detailed skin examination continues to be fundamental to properly diagnose all the cutaneous manifestations of LE and differentiate other skin conditions with skin biopsies.

Further details related to diagnosis are provided in the report…

Cutaneous Lupus Erythematosus Epidemiology

The epidemiology forecast model of Cutaneous Lupus Erythematosus for the 7MM and China is based on the analysis of the diagnosed prevalent cases of Cutaneous Lupus Erythematosus, further segmented by gender, type, and severity-specific cases.

As the market is derived using the patient-based model, the Cutaneous Lupus Erythematosus epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus, Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus by Gender, Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus by Type, Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus by Severity, and Total Treated Cases of Cutaneous Lupus Erythematosus in the 7MM and China covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, Japan, and China from 2021 to 2034. The total diagnosed prevalent cases of Cutaneous Lupus Erythematosus in the 7MM and China comprised approximately 1,467,900 cases in 2022 and are projected to increase during the forecasted period.

• The total diagnosed prevalent cases of Cutaneous Lupus Erythematosus in the United States were around 452,000 cases in 2022.
• Among the EU4 countries, the UK accounted for the largest number of Cutaneous Lupus Erythematosus cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• According to DelveInsight estimates, Japan had around 19,055 and 46,652 diagnosed prevalent male and female cases, respectively, in 2022. These cases are projected to increase during the forecasted period.
• In China, the total diagnosed prevalent cases of Cutaneous Lupus Erythematosus by severity were 352,375, 250,728, and 74,541 in mild, moderate, and severe, respectively, in 2022, which are likely to increase during throw forecasted period.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on Cutaneous Lupus Erythematosus evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, drug uptake along with challenges related to accessibility, including Medical/scientific writers, Medical Oncologists and Professors, Pediatric Rheumatologists, Lupus Foundation, and Others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM and China. Centers such as MD Anderson Cancer Center, Texas from UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Cutaneous Lupus Erythematosus market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Cutaneous Lupus Erythematosus, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• A detailed review of the Cutaneous Lupus Erythematosus epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Cutaneous Lupus Erythematosus Report Insights

• Cutaneous Lupus Erythematosus Patient Population
• Patient Population by Gender, Type, and Severity-specific Cases
• Country-wise Epidemiology Distribution

Cutaneous Lupus Erythematosus Report Key Strengths

• Ten years Forecast
• The 7MM and China Coverage
• Cutaneous Lupus Erythematosus Epidemiology Segmentation
• Cutaneous Lupus Erythematosus Report Assessment
• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Cutaneous Lupus Erythematosus? What will be the growth opportunities across the 7MM and China with respect to the patient population of Cutaneous Lupus Erythematosus?
• What is the historical and forecasted Cutaneous Lupus Erythematosus patient pool in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan, and China?
• Why do only limited patients appear with symptoms? Why is the current year diagnosis rate not high?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Cutaneous Lupus Erythematosus Market.
• To understand key opinion leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.